Veterinary Therapeutics Market (Product Type - Drugs (Anti-invectives’, Anti-inflammatory, Parasiticides), Vaccines (Inactivated Vaccines, Live Attenuated Vaccines, Recombinant Vaccines), Medicated Feed Additives (Amino Acids, Antibiotics); Animal Type - Companion Animals, Livestock Animals; Route of Administration - Oral, Parenteral, Topical; Distribution Channel - Veterinary Hospitals, Veterinary Clinics, Pharmacies & Drug Stores) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019 - 2030

Description

Research & Development Activities and Commercialization of New Products to Propel Market Growth

For several decades, veterinary vaccines have played a key role in improving food security and as a result, human health. The medicine sphere wherein veterinary medicines constitute a significant share continues to evolve at a consistent pace. At present, innovations in the veterinary therapeutics market are largely made possible through advancements in technology and research & development activities. Over the past decade, a considerable amount of promising breakthroughs in the veterinary therapeutic field have paved the way for a host of specialty medicine. The significant rise in the number of pet animals worldwide, progress in surgical and medical capabilities pertaining to the treatment of animals, growing focus on improving the overall wellness of animals, significant progress in the development of new vaccines for an array of diseases, and discovery of new medication to curb the occurrence of new diseases are some of the key factors expected to influence the expansion of the veterinary therapeutics market during the forecast period.

Companies involved in the current veterinary therapeutics market landscape are actively engaged in research and development activities that have offered considerable promise. However, one of the glaring challenges that market participants are required to negotiate their way through is the evolving regulatory framework. Product development is likely to remain the cornerstone of the growth of the global veterinary therapeutics market, which is expected to reach US$ 58.5 Bn mark by the end of 2027.

Breakthrough in Delivery of DNA Vaccines to Combat Avian Pathogens to Augment Market

Veterinary therapeutics have evolved at a considerable pace over the past decade, as drug developers continue to improve the overall efficacy of their products. Moreover, cost-efficiency, ease of administration, and suitability for mass vaccination are some of the other areas that have gained a great amount of consideration during the drug development phase. In recent times, DNA vaccines have offered significant promise as an ideal solution for different poultry diseases, as they have exhibited no reversion to virulence and infection. At present, DNA vaccines have started to gain a great amount of traction, as they can be deployed against an array of pathogens and are comparatively easier to develop, manufacture, and store. However, despite offering these advantages, the adoption of DNA vaccines could slow down, owing to lack of capacity to induce high immunity and lack of availability for large-scale vaccination in the current scenario.

Get a glimpse of the in-depth analysis through our Report Brochure

Vaccines and the development of new drugs will continue to progress at a consistent pace during the forecast period. Presently, in terms of product type, drugs are set to retain the majority of the share of the veterinary therapeutics market– a trend that is expected to continue during the forecast period. Although drugs will remain popular, the development of new vaccines will gain considerable momentum. DNA vaccines to address diseases in poultry are predominantly for combating bacterial, viral, and protozoan diseases. Although DNA vaccines to tackle poultry diseases have gained momentum since 1993, FDA approval for these vaccines has gathered pace only in the past decade. Clinical trials and added research and development activities will continue to boost the adoption of vaccines within the global veterinary therapeutics market in the coming years.

Companies to Rely on Inorganic Growth Strategies to Gain Ground

Companies operating in the current veterinary therapeutics market are expected to increase their market share by relying on inorganic growth strategies such as mergers & acquisitions. While expanding the product portfolio will continue to be an integral part of growth strategies for participants operating in the current market landscape, commercialization and development of new veterinary therapeutics are expected to gain momentum. For instance, in July 2019, Elanco Animal Health Incorporated announced that the company has completed the acquisition of Aratana Therapeutics. With the acquisition, Elanco could expand its product portfolio and gain the exclusive rights to manufacture, develop, and commercialize the ‘cash cow’ Galliprant. While drug development will continue to revolve around companion animals as well as livestock animals, market participants are anticipated to continue to improve the efficacy of their veterinary therapeutics during the forecast period.

Analysts’ Viewpoint

The global veterinary therapeutics market is expected to grow at a CAGR of ~6% during the forecast period. Some of the major factors that are likely to propel the market growth include growing demand for improved drugs, rise in the number of companion animals worldwide, improvements in surgical and medical capabilities of treatments for companion animals, development of products to combat new diseases, and growing emphasis on wellness and prevention of diseases in animals. Companies operating in the current market landscape should focus on expanding their product portfolio, investing in the development of DNA vaccines, and adopting inorganic growth strategies, including mergers & acquisitions to gain steady ground in the veterinary therapeutics market.

Veterinary Therapeutics Market: Overview

Veterinary therapeutics is a branch of animal healthcare that deals with prevention, treatment, and alleviation of several diseases. The veterinary therapeutics market consists of drugs for the treatment of animal diseases, vaccines for the prevention of various pathological conditions, and feed additives to maintain the overall well-being of animals by providing all the necessary nutrients required to lead a long, healthy life.

The drugs segment includes anti-infective, anti-inflammatory, parasiticides, and others. Different types of vaccines such as inactivated vaccine, live attenuated vaccine, recombinant vaccine, and others are used in the treatment of veterinary disorders.

Global demand for veterinary drugs, vaccines, and medicated feed additives to prevent, treat, and manage different animal diseases has reached an all-time high. Rapid increase in number of animal diseases, rise in companion animal ownership, and high prevalence of zoonotic diseases have fueled the demand for high quality veterinary therapeutics. According to the National Pet Owners Survey, conducted by American Pet Products Association (APPA), in 2017, around 68% of households in the U.S. owned a companion animal or pet.

Moreover, increase in investments in research & development of novel drugs and vaccines by private and government bodies is also expected to propel the market in the near future

However, low research and development (R&D) returns resulting in aging product portfolio, stringent regulatory framework, and rising concern about the use of antibiotics and growth promoters in food animals are some of the restraints of the veterinary therapeutics market

Market Segmentation: Veterinary Therapeutics Market

Based on product type, the global veterinary therapeutics market has been divided into drugs (anti-infective, anti-inflammatory, parasiticides, and others), vaccines (inactivated vaccines, live attenuated vaccines, recombinant vaccines, and others), and medicated feed additives (amino acids, antibiotics, and others)

In terms of animal, the global veterinary therapeutics market has been classified into companion animal and livestock animal

Based on route of administration, the global veterinary therapeutics market has been divided into oral, parenteral, and topical

In terms of distribution channel, the global veterinary therapeutics market has been categorized into veterinary hospitals, veterinary clinic, pharmacies & drug stores, and others

Each of the segments has been analyzed in detail for market trends, recent trends and developments, drivers, restraints, opportunities, and useful insights. The report provides current and future revenue (US$ Mn) for each of these segments from 2017 to 2027, considering 2018 as the base year. The compound annual growth rate (% CAGR) has been provided for each segment and market from 2019 to 2027 along with market size estimations.

Regional Overview: Veterinary Therapeutics Market

In terms of region, the global veterinary therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been divided into major countries and sub-regions.

The current and future market value in terms of revenue (US$ Mn) of these regional markets and their major countries have been provided in the report from 2017 to 2027, with their CAGRs from 2019 to 2027

The study also offers a list of recommendations, highlights, and useful insights of the market which would help new companies willing to enter the market and existing companies to increase market shares and decision-making process

Major Players

The report concludes with the company profiles section that includes key information about major players in the market

Leading players analyzed in the report include

  • Zoetis, Inc.
  • Merck Animal Health
  • Elanco Animal Health
  • Boehringer Ingelheim GmbH
  • Ceva Santé Animale
  • Virbac
  • Vetoquinol S.A.
  • Dechra Pharmaceuticals PLC
  • Biovac
  • The Chanelle Group
  • ImmuCell Corporation.

Key Questions Answered in Veterinary Therapeutics Market Report

  • What is the sales/revenue generated by veterinary therapeutics across all regions during the forecast period?
  • What are the opportunities in the veterinary therapeutics market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which region is set to expand at the fastest CAGR during the forecast period?
  • Which product segment is expected to generate the highest revenue globally in 2027? Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Veterinary Therapeutics Market - Segmentation

Product Type

  • Drugs
  • Anti-infective
  • Anti-inflammatory
  • Parasiticides
  • Others
  • Vaccines
  • Inactivated Vaccine
  • Live Attenuated Vaccine
  • Recombinant Vaccine
  • Others
  • Medicated Feed Additives
  • Antibiotics
  • Amino Acids
  • Others

Animal

  • Companion Animal
  • Livestock Animal

Route of Administration

  • Oral
  • Parenteral
  • Topical

Distribution Channel

  • Veterinary Hospitals
  • Veterinary Clinics
  • Pharmacies & Drug Stores
  • Others

Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

TABLE OF CONTENT

 1. Preface

     1.1. Report Scope and Market Segmentation 

     1.2. Research Highlights

 2. Assumptions and Research Methodology 

     2.1. Assumptions

     2.2. Research Methodology

 3. Executive Summary

     3.1. Global Veterinary Therapeutics Market Snapshot

 4. Market Overview

     4.1. Product Overview

     4.2. Key Industry Events

     4.3. Market Dynamics

         4.3.1. Drivers and Restraints Snapshot Analysis

         4.3.2. Drivers

         4.3.3. Restraints 

         4.3.4. Opportunities 

     4.4. Porter’s Five Forces Analysis 

     4.5. Value Chain Analysis

     4.6. Global Veterinary Therapeutics Market Outlook

 5. Market Outlook

     5.1. U.S. Pet Ownership Statistics, 2017

     5.2. Cat and Dog Annual Expenditures, 2017

     5.3. United States Pet Expenditures

 6. Global Veterinary Therapeutics Market Analysis, by Product Type

     6.1. Key Findings

     6.2. Introduction

     6.3. Global Veterinary Therapeutics Market Value Share Analysis, by Product Type

     6.4. Global Veterinary Therapeutics Market Forecast, by Product Type

         6.4.1. Drugs

         6.4.2. Vaccines

         6.4.3. Medicated Feed Additives 

     6.5. Global Veterinary Therapeutics Market Analysis, by Product Type 

     6.6. Global Veterinary Therapeutics Market Value (US$ Mn) Forecast, by Drugs, 2017–2030

         6.6.1. Anti-infective

         6.6.2. Anti-inflammatory

         6.6.3. Parasiticides

         6.6.4. Others

     6.7. Global Veterinary Therapeutics Market Analysis, by Drugs

     6.8. Global Veterinary Therapeutics Market Forecast, by Vaccines, 2017–2030

         6.8.1. Inactivated Vaccines

         6.8.2. Live Attenuated Vaccines

         6.8.3. Recombinant Vaccines

         6.8.4. Others

     6.9. Global Veterinary Therapeutics Market Analysis, by Vaccines

     6.10. Global Veterinary Medicated Feed Additives Market Forecast, by Medicated Feed Additives

         6.10.1. Antibiotics 

         6.10.2. Amino Acids

         6.10.3. Others

     6.11. Global Veterinary Medicated Feed Additives Market Analysis, by Medicated Feed Additives

     6.12. Global Veterinary Therapeutics Market Attractiveness Analysis, by Product Type

     6.13. Key Trends

 7. Global Veterinary Therapeutics Market Analysis, by Animal

     7.1. Key Findings

     7.2. Introduction 

     7.3. Global Veterinary Therapeutics Market Value Share Analysis, by Animal

     7.4. Global Veterinary Therapeutics Market Forecast, by Animal

         7.4.1. Companion Animal

         7.4.2. Livestock Animal

     7.5. Veterinary Therapeutics Market Forecast, by Animal

     7.6. Veterinary Therapeutics Market Attractiveness Analysis, by Animal

     7.7. Key Trends

 8. Veterinary Therapeutics Market Analysis, by Route of Administration

     8.1. Key Findings

     8.2. Introduction 

     8.3. Global Veterinary Therapeutics Market Value Share Analysis, by Route of Administration, 2018 and 2030

     8.4. Global Veterinary Therapeutics Market Value (US$ Mn) Forecast,  by Route of Administration, 2017–2030

         8.4.1. Oral

         8.4.2. Parenteral

         8.4.3. Topical

     8.5. Veterinary Therapeutics Market Forecast, by Route of Administration

     8.6. Veterinary Therapeutics Market Attractiveness Analysis, by Route of Administration, 2019-2030

     8.7. Key Trends

 9. Global Veterinary Therapeutics Market Analysis, by Distribution Channel

     9.1. Key Findings

     9.2. Introduction 

     9.3. Global Veterinary Therapeutics Market Value Share Analysis, by Distribution Channel

     9.4. Global Veterinary Therapeutics Market Forecast, by Distribution Channel

         9.4.1. Veterinary Hospitals

         9.4.2. Veterinary Clinics

         9.4.3. Pharmacies & Drug stores

         9.4.4. Others

     9.5. Global Veterinary Therapeutics Market Forecast, by Distribution Channel

     9.6. Global Veterinary Therapeutics Market Attractiveness Analysis, by Distribution Channel

     9.7. Key Trends

 10. Global Veterinary Therapeutics Market Analysis, by Region

     10.1. Global Veterinary Therapeutics Market Snapshot, by Country

     10.2. Global Veterinary Therapeutics Market Value Share Analysis, by Region

     10.3. Global Veterinary Therapeutics Market Forecast, by Region

         10.3.1. North America

         10.3.2. Europe

         10.3.3. Asia Pacific

         10.3.4. Latin America

         10.3.5. Middle East & Africa

     10.4. Global Veterinary Therapeutics Market Attractiveness Analysis, by Region

 11. North America Veterinary Therapeutics Market Analysis

     11.1. Key Findings

     11.2. North America Veterinary Therapeutics Market Overview

     11.3. North America Veterinary Therapeutics Market Value Share Analysis, by Product Type

     11.4. North America Veterinary Therapeutics Market Forecast, by Product Type

         11.4.1. Drugs

             11.4.1.1. Anti-infective

             11.4.1.2. Anti-inflammatory

             11.4.1.3. Parasiticides

             11.4.1.4. Others

         11.4.2. Vaccines

             11.4.2.1. Inactivated Vaccines

             11.4.2.2. Live Attenuated Vaccines

             11.4.2.3. Recombinant Vaccines

             11.4.2.4. Others

         11.4.3. Medicated Feed Additives

             11.4.3.1. Antibiotics 

             11.4.3.2. Amino Acids

             11.4.3.3. Others

     11.5. North America Veterinary Therapeutics Market Value Share Analysis, by Animal

     11.6. North America Veterinary Therapeutics Market Forecast, by Animal

         11.6.1. Companion Animal

         11.6.2. Livestock Animal

     11.7. North America Veterinary Therapeutics Market Value Share Analysis, by Route of Administration

     11.8. North America Veterinary Therapeutics Market Forecast, by Route of Administration

         11.8.1. Oral

         11.8.2. Parenteral

         11.8.3. Topical

     11.9. North America Veterinary Therapeutics Market Value Share Analysis, by Distribution Channel

     11.10. North America Veterinary Therapeutics Market Forecast, by Distribution Channel

         11.10.1. Veterinary Hospitals

         11.10.2. Veterinary Clinics

         11.10.3. Pharmacies & Drug Stores

         11.10.4. Others

     11.11. North America Veterinary Therapeutics Market Value Share Analysis, by Country

         11.11.1. U.S.

         11.11.2. Canada

     11.12. North America Veterinary Therapeutics Market Attractiveness Analysis

     11.13. Market Trends

 12. Europe Veterinary Therapeutics Market Analysis

     12.1. Key Findings

     12.2. Europe Veterinary Therapeutics Market Overview

     12.3. Europe Veterinary Therapeutics Market Value Share Analysis, by Product Type

     12.4. Europe Veterinary Therapeutics Market Forecast, by Product Type

         12.4.1. Drugs

             12.4.1.1. Anti-infective

             12.4.1.2. Anti-inflammatory

             12.4.1.3. Parasiticides

             12.4.1.4. Others

         12.4.2. Vaccines

             12.4.2.1. Inactivated Vaccines

             12.4.2.2. Live Attenuated Vaccines

             12.4.2.3. Recombinant Vaccines

             12.4.2.4. Others

         12.4.3. Medicated Feed Additives

             12.4.3.1. Antibiotics 

             12.4.3.2. Amino Acids

             12.4.3.3. Others

     12.5. Europe Veterinary Therapeutics Market Value Share Analysis, by Animal

     12.6. Europe Veterinary Therapeutics Market Forecast, by Animal

         12.6.1. Companion Animal

         12.6.2. Livestock Animal

     12.7. Europe Veterinary Therapeutics Market Value Share Analysis, by Route of Administration

     12.8. Europe Veterinary Therapeutics Market Forecast, by Route of Administration

         12.8.1. Oral

         12.8.2. Parenteral

         12.8.3. Topical

     12.9. Europe Veterinary Therapeutics Market Value Share Analysis, by Distribution Channel

     12.10. Europe Veterinary Therapeutics Market Forecast, by Distribution Channel

         12.10.1. Veterinary Hospitals

         12.10.2. Veterinary Clinics

         12.10.3. Pharmacies & Drug Stores

         12.10.4. Others

     12.11. Europe Veterinary Therapeutics Market Value Share Analysis, by Country/Sub-region

         12.11.1. U.K.

         12.11.2. Germany

         12.11.3. Italy

         12.11.4. France

         12.11.5. Spain

         12.11.6. Rest of Europe

     12.12. Europe Veterinary Therapeutics Market Attractiveness Analysis

     12.13. Market Trends

 13. Asia Pacific Veterinary Therapeutics Market Analysis

     13.1. Key Findings

     13.2. Asia Pacific Veterinary Therapeutics Market Overview

     13.3. Asia Pacific Veterinary Therapeutics Market Value Share Analysis, by Product Type

     13.4. Asia Pacific Veterinary Therapeutics Market Forecast, by Product Type

         13.4.1. Drugs

             13.4.1.1. Anti-infective

             13.4.1.2. Anti-inflammatory

             13.4.1.3. Parasiticides

             13.4.1.4. Others

         13.4.2. Vaccines

             13.4.2.1. Inactivated Vaccines

             13.4.2.2. Live Attenuated Vaccines

             13.4.2.3. Recombinant Vaccines

             13.4.2.4. Others

         13.4.3. Medicated Feed Additives

             13.4.3.1. Antibiotics 

             13.4.3.2. Amino Acids

             13.4.3.3. Others

     13.5. Asia Pacific Veterinary Therapeutics Market Value Share Analysis, by Animal

     13.6. Asia Pacific Veterinary Therapeutics Market Forecast, by Animal

         13.6.1. Companion Animal

         13.6.2. Livestock Animal

     13.7. Asia Pacific Veterinary Therapeutics Market Value Share Analysis, by Route of Administration

     13.8. Asia Pacific Veterinary Therapeutics Market Forecast, by Route of Administration

         13.8.1. Oral

         13.8.2. Parenteral

         13.8.3. Topical

     13.9. Asia Pacific Veterinary Therapeutics Market Value Share Analysis, by Distribution Channel

     13.10. Asia Pacific Veterinary Therapeutics Market Forecast, by Distribution Channel

         13.10.1. Veterinary Hospitals

         13.10.2. Veterinary Clinics

         13.10.3. Pharmacies & Drug Stores

         13.10.4. Others

     13.11. Asia Pacific Veterinary Therapeutics Market Value Share Analysis, by Country/Sub-region

         13.11.1. China

         13.11.2. Japan

         13.11.3. India

         13.11.4. Australia & New Zealand

         13.11.5. Rest of Asia Pacific

     13.12. Asia Pacific Veterinary Therapeutics Market Attractiveness Analysis

     13.13. Market Trends

 14. Latin America Veterinary Therapeutics Market Analysis

     14.1. Key Findings

     14.2. Latin America Veterinary Therapeutics Market Overview

     14.3. Latin America Veterinary Therapeutics Market Value Share Analysis, by Product Type

     14.4. Latin America Veterinary Therapeutics Market Forecast, by Product Type

         14.4.1. Drugs

             14.4.1.1. Anti-infective

             14.4.1.2. Anti-inflammatory

             14.4.1.3. Parasiticides

             14.4.1.4. Others

         14.4.2. Vaccines

             14.4.2.1. Inactivated Vaccines

             14.4.2.2. Live Attenuated Vaccines

             14.4.2.3. Recombinant Vaccines

             14.4.2.4. Others

         14.4.3. Medicated Feed Additives

             14.4.3.1. Antibiotics 

             14.4.3.2. Amino Acids

             14.4.3.3. Others

     14.5. Latin America Veterinary Therapeutics Market Value Share Analysis, by Animal

     14.6. Latin America Veterinary Therapeutics Market Forecast, by Animal

         14.6.1. Companion Animal

         14.6.2. Livestock Animal

     14.7. Latin America Veterinary Therapeutics Market Value Share Analysis, by Route of Administration

     14.8. Latin America Veterinary Therapeutics Market Forecast, by Route of Administration

         14.8.1. Oral

         14.8.2. Parenteral

         14.8.3. Topical

     14.9. Latin America Veterinary Therapeutics Market Value Share Analysis, by Distribution Channel

     14.10. Latin America Veterinary Therapeutics Market Forecast, by Distribution Channel

         14.10.1. Veterinary Hospitals

         14.10.2. Veterinary Clinics

         14.10.3. Pharmacies & Drug Stores

         14.10.4. Others

     14.11. Latin America Veterinary Therapeutics Market Value Share Analysis, by Country/Sub-region

         14.11.1. Brazil

         14.11.2. Mexico

         14.11.3. Rest of Latin America

     14.12. Latin America Veterinary Therapeutics Market Attractiveness Analysis

     14.13. Market Trends

 15. Middle East & Africa Veterinary Therapeutics Market Analysis

     15.1. Key Findings

     15.2. Middle East & Africa Veterinary Therapeutics Market Overview

     15.3. Middle East & Africa Veterinary Therapeutics Market Value Share Analysis, by Product Type

     15.4. Middle East & Africa Veterinary Therapeutics Market Forecast, by Product Type

         15.4.1. Drugs

             15.4.1.1. Anti-infective

             15.4.1.2. Anti-inflammatory

             15.4.1.3. Parasiticides

             15.4.1.4. Others

         15.4.2. Vaccines

             15.4.2.1. Inactivated Vaccines

             15.4.2.2. Live Attenuated Vaccines

             15.4.2.3. Recombinant Vaccines

             15.4.2.4. Others

         15.4.3. Medicated Feed Additives

             15.4.3.1. Antibiotics 

             15.4.3.2. Amino Acids

             15.4.3.3. Others

     15.5. Middle East & Africa Veterinary Therapeutics Market Value Share Analysis, by Animal

     15.6. Middle East & Africa Veterinary Therapeutics Market Forecast, by Animal

         15.6.1. Companion Animal

         15.6.2. Livestock Animal

     15.7. Middle East & Africa Veterinary Therapeutics Market Value Share Analysis, by Route of Administration

     15.8. Middle East & Africa Veterinary Therapeutics Market Forecast, by Route of Administration

         15.8.1. Oral

         15.8.2. Parenteral

         15.8.3. Topical

     15.9. Middle East & Africa Veterinary Therapeutics Market Value Share Analysis, by Distribution Channel

     15.10. Middle East & Africa Veterinary Therapeutics Market Forecast, by Distribution Channel

         15.10.1. Veterinary Hospitals

         15.10.2. Veterinary Clinics

         15.10.3. Pharmacies & Drug Stores

         15.10.4. Others

     15.11. Middle East & Africa Veterinary Therapeutics Market Value Share Analysis, by Country/Sub-region

         15.11.1. Brazil

         15.11.2. Mexico

         15.11.3. Rest of Middle East & Africa

     15.12. Middle East & Africa Veterinary Therapeutics Market Attractiveness Analysis

     15.13. Market Trends

 16. Competition Analysis

     16.1. Global Veterinary Therapeutics Market Share Analysis, by Company

     16.2. Competition Matrix

     16.3. Company Profile

         16.3.1. Boehringer Ingelheim GmbH 

             16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

             16.3.1.2. Financial Overview

             16.3.1.3. Product Portfolio

             16.3.1.4. SWOT Analysis

             16.3.1.5. Strategic Overview

         16.3.2. Merck Animal Health

             16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

             16.3.2.2. Financial Overview

             16.3.2.3. Product Portfolio

             16.3.2.4. SWOT Analysis

             16.3.2.5. Strategic Overview

         16.3.3. Zoetis Inc. 

             16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

             16.3.3.2. Financial Overview

             16.3.3.3. Product Portfolio

             16.3.3.4. SWOT Analysis

             16.3.3.5. Strategic Overview

         16.3.4. Eli Lilly and Company (Elanco Animal Health) 

             16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

             16.3.4.2. Financial Overview

             16.3.4.3. Product Portfolio

             16.3.4.4. SWOT Analysis

             16.3.4.5. Strategic Overview

         16.3.5. Ceva Santé Animale 

             16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

             16.3.5.2. Financial Overview

             16.3.5.3. Product Portfolio

             16.3.5.4. SWOT Analysis

             16.3.5.5. Strategic Overview

         16.3.6. Virbac 

             16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

             16.3.6.2. Financial Overview

             16.3.6.3. Product Portfolio

             16.3.6.4. SWOT Analysis

             16.3.6.5. Strategic Overview

         16.3.7. Vetoquinol S.A. 

             16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

             16.3.7.2. Financial Overview

             16.3.7.3. Product Portfolio

             16.3.7.4. SWOT Analysis

             16.3.7.5. Strategic Overview

         16.3.8. Dechra Pharmaceuticals PLC 

             16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

             16.3.8.2. Financial Overview

             16.3.8.3. Product Portfolio

             16.3.8.4. SWOT Analysis

             16.3.8.5. Strategic Overview

         16.3.9. Biovac 

             16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

             16.3.9.2. Financial Overview

             16.3.9.3. Product Portfolio

             16.3.9.4. SWOT Analysis

             16.3.9.5. Strategic Overview

         16.3.10. The Chanelle Group 

             16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

             16.3.10.2. Financial Overview

             16.3.10.3. Product Portfolio

             16.3.10.4. SWOT Analysis

             16.3.10.5. Strategic Overview

         16.3.11. ImmuCell Corporation

             16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)

             16.3.11.2. Financial Overview

             16.3.11.3. Product Portfolio

             16.3.11.4. SWOT Analysis

             16.3.11.5. Strategic Overview

Choose License Type

Checkout Inquiry Sample